- Citations, last 5 years
- 596
- Works, last 5 years
- 40
- h-index
- 48
- Scientists listed
- 13
- Grants since 2016
- 64
Grants received
2017–2020 · research · R44
Advancement to IND of novel BLI for pairing with cefixime
Luigi Xerri · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2017–2020 · research · R44
Advancement to IND of novel BLI for pairing with cefixime
Luigi Xerri · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2016–2020 · contract · N01
Development of Therapeutics for Biodefense and Emerging Infectious Diseases
Timothy Henkel · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2016–2022 · contract · N01
Development of Therapeutics for Biodefense and Emerging Infectious Diseases
Timothy Henkel · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2016–2019 · research · R44
Advancement to Clinical Candidate of Novel, Potent and Selective Chikungunya virus inhibitor series
Daniel C Pevear · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2016–2018 · research · R43
Discovery of inhibitors of BK polyomavirus
Glen Andrew Coburn · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2016–2026 · contract · N01
Development of Therapeutic Products for Biodefense and Emerging Antibiotic-Resistant Infectious Diseases
C Fernando D Oliveira · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2016–2020 · contract · N01
Development of Therapeutics for Biodefense and Emerging Infectious Diseases
Timothy Henkel · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2016–2024 · contract · N01
Development of Therapeutics for Antimicrobial Resistant Pathogens
Timothy Henkel · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2016–2020 · contract · N01
Development of Therapeutics for Biodefense and Emerging Infectious Diseases
Timothy Henkel · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2016–2019 · research · R44
Advancement to Clinical Candidate of Novel, Potent and Selective Chikungunya virus inhibitor series
Daniel C Pevear · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2016–2022 · contract · N01
Development of Therapeutics for Biodefense and Emerging Infectious Diseases
Timothy Henkel · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2016–2020 · contract · N01
Development of Therapeutics for Biodefense and Emerging Infectious Diseases
Timothy Henkel · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2016–2018 · research · R43
Discovery of inhibitors of BK polyomavirus
Glen Andrew Coburn · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2016–2022 · contract · N01
Development of Therapeutics for Biodefense and Emerging Infectious Diseases
Timothy Henkel · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2016–2019 · research · R44
Advancement to Clinical Candidate of Novel, Potent and Selective Chikungunya virus inhibitor series
Daniel C Pevear · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2016–2019 · contract · N01
Development of Therapeutics for Biodefense and Emerging Infectious Diseases
Timothy Henkel · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2016–2026 · contract · N01
Development of Therapeutic Products for Biodefense and Emerging Antibiotic-Resistant Infectious Diseases
Timothy Henkel · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2015–2021 · research · R44
Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas
Christopher John Burns · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2015–2022 · research · R44
Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas
Christopher John Burns · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2015–2023 · research · R44
Advancement of antiviral inhibitors of chikungunya virus
Daniel C Pevear · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2015–2022 · research · R44
Advancement of antiviral inhibitors of chikungunya virus
Daniel C Pevear · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2015–2021 · research · R44
Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas
Christopher John Burns · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health
2015–2022 · research · R44
Advancement of antiviral inhibitors of chikungunya virus
Daniel C Pevear · VenatoRx Pharmaceuticals (United States) · funded by National Institutes of Health